Aim
To assess changes in skin conductance during retinopathy of prematurity screening and to study the correlation between the skin conductance and a validated pain scale.
Methods
Prospective observational study. Fifty‐three eye examinations were performed in 32 preterm infant candidates for retinopathy of prematurity screening. Outcome measures were changes in Premature Infant Pain Profile‐Revised (PIPP‐R) scale and number of skin conductance fluctuations.
Results
There was a significant increase from baseline in the number of skin conductance fluctuations and PIPP‐R during the procedure. The maximum value of number of skin conductance fluctuations was 0.64 ± 0.44 peaks/sec, and the maximum value of PIPP‐R was 10.8 ± 3.3.
A correlation between the skin conductance and PIPP‐R was not found at any time during the eye examination. Repeated measures correlation analyses showed only a moderate positive correlation between PIPP‐R and number of skin conductance fluctuation values.
Conclusion
There were significant changes in both PIPP‐R and number of skin conductance fluctuations during retinopathy of prematurity screening, reaffirming that this procedure is painful and stressful. The number of skin conductance fluctuations and PIPP‐R are not significantly correlated, which likely reflects that these parameters evaluate different but complementary aspects of neonatal pain responses.
An actual increase of 4.1% was observed in the cases with an identified aetiological agent after implementing the Norovirus GI+GII CerTest diagnostic technique. The most common cause of acute gastroenteritis is rotavirus, closely followed by norovirus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.